Results 231 to 240 of about 7,329,727 (241)

Characteristics of patients with asthma using single inhaler triple therapy (SITT) in the USA

Airway pharmacology and treatment, 2023
Stephen G Noorduyn, Kristin Kahle-Wrobleski, Rosirene Paczkowski, Lydia Lee, Phani Veeranki, Mary Johnson, Afisi S Ismaila, Emmeline Igboekwe, Julie Nack, Noelle N Gronroos   +9 more
openaire   +1 more source

“Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study – The TRIBUNE study”

Respiratory Medicine, 2023
Konstantinos Porpodis, Petros Bakakos
exaly  

Safety of two single-inhaler triple therapies compared

Reactions Weekly
openaire   +1 more source

Comorbidities and their association with exacerbations in single inhaler triple therapy COPD patients

Minerva Respiratory Medicine
SPOSATO, Bruno, SPOSATO, Lorenzo, LACERENZA, Leonardo G., PETRUCCI, Elisa, CRESTI, Alberto, BARATTA, Pasquale, SERAFINI, Andrea, MICHELETTO, Claudio, RICCI, Alberto, SCALESE, Marco   +9 more
openaire   +1 more source

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2016
Jørgen Vestbo, Dave Singh, Massimo Corradi   +2 more
exaly  

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Lancet, The, 2019
Dave Singh, George Georges, Pierluigi Paggiaro   +2 more
exaly  

Single inhaler extra fine triple therapy versus open triple therapy in COPD: TRIPOLI observational study

Airway pharmacology and treatment
Javier López, Daniel Vega, Mercedes Segura, Esther Sánchez, Eva Cabrera, José Luis Velasco   +5 more
openaire   +1 more source

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2017
Jørgen Vestbo, Dave Singh, Massimo Corradi   +2 more
exaly  

Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study

American Journal of Medicine
Hana Müllerová, Antonio Anzueto, Claus Vogelmeier   +2 more
exaly  

Is single-inhaler triple therapy cost-effective versus multiple-inhaler triple therapy for COPD in Germany? The INTREPID trial

Airway pharmacology and treatment
Stephen G Noorduyn, Kai-Michael Beeh, Dhvani Shah, Alan Martin, Robyn Kendall, Priyadarsini Dasari, Afisi S Ismaila, Jing Claussen   +7 more
openaire   +1 more source